Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 May 31:9:941008.
doi: 10.3389/fmed.2022.941008. eCollection 2022.

Editorial: Fibrotic Lung Disease-"Lumping" the Progressive Phenotype

Tejaswini Kulkarni  1 , Sydney B Montesi  2 , Bridget F Collins  3
Affiliations
Editorial

Editorial: Fibrotic Lung Disease-"Lumping" the Progressive Phenotype

Tejaswini Kulkarni et al. Front Med (Lausanne). .
No abstract available

Keywords: antifibrotic therapy; idiopathic pulmonary fibrosis; immunosuppression; interstitial lung diseases; progressive pulmonary fibrosis.

PubMed Disclaimer

Conflict of interest statement

TK has received speaker fees from Boehringer Ingelheim Pharmaceuticals, Inc. and consulting fees from Puretech, Inc. and United Therapeutics Inc., outside the submitted work. SM was funded by NIH/NHLBI (K23HL15033) and reports research funding from Pliant Therapeutics, Merck, United Therapeutics, and Boehringer Ingelheim, consulting fees from DevPro Biopharma, Gilead Sciences, and Roche, and royalties from Wolters Kluwer, outside the submitted work. BC has received consulting fees from Boehringer Ingelheim Pharmaceuticals, Inc, outside the submitted work.

Comment on

  • Editorial on the Research Topic Fibrotic Lung Disease—“Lumping” the Progressive Phenotype

References

    1. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. . Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. (2022) 205:e18–e47. 10.1164/rccm.202202-0399ST - DOI - PMC - PubMed
    1. Chan C, Ryerson CJ, Dunne JV, Wilcox PG. Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study. BMC Pulm Med. (2019) 19:192. 10.1186/s12890-019-0943-2 - DOI - PMC - PubMed
    1. Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, et al. . Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. (2016) 47:588–96. 10.1183/13993003.00357-2015 - DOI - PubMed
    1. Gimenez A, Storrer K, Kuranishi L, Soares MR, Ferreira RG, Pereira CA, et al. . Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax. (2018) 73:391–2. 10.1136/thoraxjnl-2017-210035 - DOI - PubMed
    1. Nasser M, Larrieu S, Boussel L, Si-Mohamed S, Bazin F, Marque S, et al. . Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study). Respir Res. (2021). 22:162. 10.1186/s12931-021-01749-1 - DOI - PMC - PubMed

Publication types

LinkOut - more resources